Clinical Trial Update: Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis [NA]

View source ↗

Summary

A clinical trial is evaluating whether adding conjugated linoleic acid and the probiotic Vivomixx to first-line immunotherapy improves outcomes in relapsing-rem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Conjugated linoleic acid (CLA) (Conjugated linoleic acid)
• Vivomixx (Probiotic formulation)

Snippet

Sponsor: Universität Münster | Conditions: Multiple Sclerosis, Relapsing-Remitting | NA | Status: RECRUITING